US stocks recently ushered in a peak of Chinese companies going to the US, March 9$Xiao-I (AIXI.US)$Successfully landed on NASDAQ,$ICZOOM Group (IZM.US)$,$Intchains Group (ICG.US)$It also went public one after another last week. Furthermore,$YanGuFang International Group (YGF.US)$,$Jin Medical International (ZJYL.US)$and$U Power (UCAR.US)$The subscription has started.

Yan Gufang opens subscription and is expected to go on sale on March 21

Established in 2012, Yangufang is mainly engaged in the production, development and sale of oat and cereal products. Its direct sales team and distribution network are spread all over China. Products include oatmeal, oat powder, oat bran, oat nutritional health products (oat peptides series, dietary fiber powder, oat toothpaste), etc. Yangufang has operations in Beijing, Shanghai, Jiangsu, Zhejiang, Fujian, Guangdong, Inner Mongolia, Anhui and Chongqing, and expanded international sales in the US in October 2022.

According to the prospectus, Yangufang's revenue for the 2021 and 2022 fiscal years (the end date of the fiscal year is June 30) was 29.837 million and 3.682 million US dollars, respectively. The company plans to issue 2.5 million shares at a price of $4-6 each, and is expected to go public on March 21, EST.

Zhongjin Medical began purchasing and is expected to go on sale on March 24

Established in 2006, Zhongjin Medical mainly designs and manufactures wheelchairs and life support products such as oxygen concentrators and bathing machines for the disabled, the elderly, and those recovering from injuries and illnesses. Among them, most of the company's products are sold to distributors in Japan and China, and only a small number of products are sold to the United States, Canada, Australia, South Korea, Israel, Singapore and other countries.

According to the prospectus, for the 2021 and 2022 fiscal years (ending September 30), China Jin Healthcare's revenue was 207.64 million and 19.191 million US dollars, respectively, and net profit was 2.632 million and 2,707 million US dollars respectively. The company plans to issue 1.25 million shares at a price of $8-9 each, and is expected to go public on March 24 EST.

Premium cars began to be purchased and are expected to go on sale on March 31

Premium Car is mainly engaged in providing vehicle procurement services. The company represents automobile sales between car wholesalers and buyers, including small and medium-sized car dealers and individual customers (mainly located in third- and fourth-tier cities). To this end, the company focused on establishing business relationships with the company's procurement partners and developed a vehicle procurement network.

According to the prospectus, Premium Auto's revenue in 2020, 2021, and the first six months of 2022 was 1,464 million yuan, 8.01 million yuan and 4.277 million yuan respectively. The company plans to issue 2.5 million shares at a price of $6-8 each, and is expected to go public on March 31 EST.

New Ruipeng continues to push for an IPO in the US, with revenue exceeding 5.7 billion dollars in 2022

Xinruipeng Pet Healthcare Group updated its prospectus submitted to the US Securities and Exchange Commission (SEC) on March 14 EST to continue its IPO process.

$Ruipeng Pet Group (RPET.US)$It operates the three core businesses of pet medical services, supply chain services, and local lifestyle services, and extends other business segments such as third-party diagnostics, continuing veterinary education, and industry-level enterprise services. According to Frost & Sullivan's report, based on the number of hospitals and pet care service revenue in 2021 and 2022, Xinruipeng is the largest pet care platform in China and the second largest in the world.

On the financial side, the company's revenue for 2021-2022 was 4.78 billion yuan and 5.74 billion yuan respectively. Net losses for the same period were 1.31 billion yuan and 1.42 billion yuan respectively.

In terms of fundraising purposes, the company plans to use about 35% of the net proceeds of financing to strengthen the brand, expand the pet hospital network in China, and further upgrade pet care services; about 20% will be used to explore upstream and downstream business cooperation opportunities and global expansion; about 15% will be used for research and development to enhance digitalization and technology; and about 10% will be used for working capital and other general corporate purposes.